Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study

Norihiro NishimotoOsaka Rheumatology Clinic, Tatsuno-Sinsaibashi-Building 5th Floor, 4-4-10 Minamisenba Chuo-ku, Osaka 542-0081, Japan;Department of Molecular Regulation for Intractable Disease, Institute of Medical Science, Tokyo Medical University, Tokyo, Japan;Laboratory of Immune Regulation, Wakayama Medical University, Wakayama, JapanCorrespondence[email protected] [email protected]

Koichi AmanoDepartment of Rheumatology/Clinical Immunology, Saitama Medical Centre, Saitama Medical University, Saitama, Japan

Yasuhiko HirabayashiDepartment of Rheumatology, Hikarigaoka Spellman Hospital, Sendai, Japan

Takahiko HoriuchiDepartment of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan

Tomonori IshiiDepartment of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Miyagi, Japan

Mitsuhiro IwahashiHigashihiroshima Memorial Hospital, Higashihiroshima, Japan

Masahiro IwamotoDivision of Rheumatology and Clinical Immunology, Jichi Medical University, Tochigi, Japan

Hitoshi KohsakaDepartment of Medicine and Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan

Masakazu KondoKondo Clinic of Rheumatology and Orthopaedic Surgery, Fukuoka, Japan

Tsukasa MatsubaraMatsubara Mayflower Hospital, Hyogo, Japan

Toshihide MimuraDepartment of Rheumatology and Applied Immunology, Saitama Medical University, Saitama, Japan

Hisaaki MiyaharaNational Hospital Organization Kyushu Medical Center, Fukuoka, Japan

Shuji OhtaDepartment of Rheumatology, Taga General Hospital, Ibaraki, Japan

Yukihiko SaekiNational Hospital Organization Osaka-Minami Medical Center, Osaka, Japan

Kazuyoshi SaitoThe First Department of Internal Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan

Hajime SanoDivision of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan

Kiyoshi TakasugiDohgo Spa Hospital, Ehime, Japan

Tsutomu TakeuchiDivision of Rheumatology and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine, Keio University, Tokyo, Japan

Shigeto TohmaSagamihara National Hospital, National Hospital Organization, Kanagawa, Japan

Tomomi TsuruPS Clinic, Fukuoka, Japan

Yukitaka UekiSasebo Chuo Hospital, Nagasaki, Japan

Jiro YamanaHigashihiroshima Memorial Hospital, Higashihiroshima, Japan

Jun HashimotoNational Hospital Organization Osaka-Minami Medical Center, Osaka, Japan

Takaji MatsutaniLaboratory of Immune Regulation, Wakayama Medical University, Wakayama, Japan

Miho MurakamiDepartment of Molecular Regulation for Intractable Disease, Institute of Medical Science, Tokyo Medical University, Tokyo, Japan;Laboratory of Immune Regulation, Wakayama Medical University, Wakayama, Japan

Nobuhiro TakagiChugai Pharmaceutical Co. Ltd., Tokyo, Japan

show all

Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study

Reprints and Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date